Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge

Enhance Your Career with Our Premier Toxicology Course! The highly acclaimed Practical Application of Toxicology in Drug Development (PATDD) course co-organised by Cambridge Academy of Therapeutic Sciences (CATS) and The British Toxicology Society (BTS) provides comprehensive training in toxicology as applied to drug development, catering to scientists from around the globe. Participants will gain a thorough understanding of non-clinical safety evaluation principles, with a strong focus on practical applications and interpreting safety data. Both European and US regulatory toxicology perspectives will be covered. Who Should Attend? This course is ideal for professionals from: ·        Biotechnology and Pharmaceutical Companies ·        Contract Research Organizations (CROs) working with both small and large molecules ·        Regulatory Agencies and Academia with an interest in toxicology and drug safety assessment ·        Early Career Scientists seeking advanced knowledge in toxicology ·        Scientists in Related Fields (e.g., chemistry, biochemistry, molecular biology, medicine) looking to transition into drug safety assessment Course Highlights ·        Virtual Interactive Case Studies and Breakout Groups ·        Live Q&A Sessions with Industry Experts ·        Unlimited On-Demand Access to Recorded Lectures and Course Course Details ·        Dates: October 7th - November 11th ·        Q&A Sessions: Weekly and Bi-weekly ·        Case Studies: 11th November ·        Registrations Open Now: Group discounts, bursary and BTS/ACT discounts available! Register here: https://shorturl.at/iy9Lo Visit our CATS website for more information regarding this course.

After the summer break, we are returning with our monthly ‘Gateway to Translation’ (G2T) series of talks, which we organise in collaboration with Translation Manchester. In the next webinar, we will explore an emerging world of RNA targeted therapeutics! On Tuesday 24th September, 2-3pm we will be hosting Dr Rabia T. K., CEO of Serna Bio. Dr Khan will be giving a talk titled “Mapping the Druggable Transcriptome: Lesson learned from AI-enabled RNA-small molecule drug discovery.” The webinar will be chaired by Prof Anne Willis OBE, MRC Investigator and the Director of the MRC Toxicology Unit. Registration link: https://lnkd.in/eTc99hV4 #RNAtargeting #drugdiscovery #smallmolecules

Secure your place on our premier toxicology course! The highly acclaimed Practical Application of Toxicology in Drug Development (PATDD) course co-organised by Cambridge Academy of Therapeutic Sciences (CATS) and The British Toxicology Society (BTS) provides comprehensive training in toxicology as applied to drug development, catering to scientists from around the globe. Participants will gain a thorough understanding of non-clinical safety evaluation principles, with a strong focus on practical applications and interpreting safety data. Both European and US regulatory toxicology perspectives will be covered. Who Should Attend? This course is ideal for professionals from: ·        Biotechnology and Pharmaceutical Companies ·        Contract Research Organizations (CROs) working with both small and large molecules ·        Regulatory Agencies and Academia with an interest in toxicology and drug safety assessment ·        Early Career Scientists seeking advanced knowledge in toxicology ·        Scientists in Related Fields (e.g., chemistry, biochemistry, molecular biology, medicine) looking to transition into drug safety assessment Course Highlights ·        Virtual Interactive Case Studies and Breakout Groups ·        Live Q&A Sessions with Industry Experts ·        Unlimited On-Demand Access to Recorded Lectures and Course Course Details ·        Dates: October 7th - November 11th ·        Q&A Sessions: Weekly and Bi-weekly ·        Case Studies: 11th November ·        Registrations Open Now: Group discounts, bursary and BTS/ACT discounts available! Register here: https://shorturl.at/iy9Lo Visit our CATS website for more information. https://lnkd.in/d9Qphv9N

Enhance Your Career with Our Premier Toxicology Course! The highly acclaimed Practical Application of Toxicology in Drug Development (PATDD) course co-organised by Cambridge Academy of Therapeutic Sciences (CATS) and The British Toxicology Society (BTS) provides comprehensive training in toxicology as applied to drug development, catering to scientists from around the globe. Participants will gain a thorough understanding of non-clinical safety evaluation principles, with a strong focus on practical applications and interpreting safety data. Both European and US regulatory toxicology perspectives will be covered. Who Should Attend? This course is ideal for professionals from: ·        Biotechnology and Pharmaceutical Companies ·        Contract Research Organizations (CROs) working with both small and large molecules ·        Regulatory Agencies and Academia with an interest in toxicology and drug safety assessment ·        Early Career Scientists seeking advanced knowledge in toxicology ·        Scientists in Related Fields (e.g., chemistry, biochemistry, molecular biology, medicine) looking to transition into drug safety assessment Course Highlights ·        Virtual Interactive Case Studies and Breakout Groups ·        Live Q&A Sessions with Industry Experts ·        Unlimited On-Demand Access to Recorded Lectures and Course Course Details ·        Dates: October 7th - November 11th ·        Q&A Sessions: Weekly and Bi-weekly ·        Case Studies: 11th November ·        Registrations Open Now: Group discounts, bursary and BTS/ACT discounts available! Register here: https://shorturl.at/iy9Lo Visit our CATS website for more information regarding this course.

Enhance Your Career with Our Premier Toxicology Course! The highly acclaimed Practical Application of Toxicology in Drug Development (PATDD) course co-organised by Cambridge Academy of Therapeutic Sciences (CATS) and The British Toxicology Society (BTS) provides comprehensive training in toxicology as applied to drug development, catering to scientists from around the globe. Participants will gain a thorough understanding of non-clinical safety evaluation principles, with a strong focus on practical applications and interpreting safety data. Both European and US regulatory toxicology perspectives will be covered. Who Should Attend? This course is ideal for professionals from: ·        Biotechnology and Pharmaceutical Companies ·        Contract Research Organizations (CROs) working with both small and large molecules ·        Regulatory Agencies and Academia with an interest in toxicology and drug safety assessment ·        Early Career Scientists seeking advanced knowledge in toxicology ·        Scientists in Related Fields (e.g., chemistry, biochemistry, molecular biology, medicine) looking to transition into drug safety assessment Course Highlights ·        Virtual Interactive Case Studies and Breakout Groups ·        Live Q&A Sessions with Industry Experts ·        Unlimited On-Demand Access to Recorded Lectures and Course Course Details ·        Dates: October 7th - November 11th ·        Q&A Sessions: Weekly and Bi-weekly ·        Case Studies: 11th November ·        Registrations Open Now: Group discounts, bursary and BTS/ACT discounts available! Register here: https://shorturl.at/iy9Lo Visit our CATS website for more information regarding this course.

We are excited to announce the upcoming the CAMS scientific symposium on ‘Alternative approaches for human-relevant toxicity assessments' on 10th July 2024 from 12:30pm. The Keynote lecture will be given by Professor Menna Clatworthy (University of Cambridge), and guest speakers from the Investigative Toxicology Leaders Forum will also be in attendance. In this event we will showcase alternative approaches and recent advances in complex in vitro models (e.g MPS) from industry and academia to complement traditional in vivo studies, and how these are used to investigate human-relevant toxicity and translate these findings to the clinic. With speakers from AZ, GSK, Bayer, Sanofi, Merck, Novartis and Abbvie, as well as expertise from the MRC’s Toxicology Unit and the Centre for Drug Safety Science, we will give a snapshot of where the field of medicines safety is going, and where we can learn from successes of the past to accelerate moving forward with novel therapeutic modalities. Please register for the event here: https://lnkd.in/e4p4yZWV

We are excited to announce another month of the G2T webinar series which is a joint initiative between CATS (University of Cambridge) and Translation Manchester (The University of Manchester). Monthly online talks are aimed to inform academics about new technologies and translational research developed in pharma/medtech/biotech sector, as well as to facilitate collaboration between academia and commercial sphere. Decently is a digital health tech startup developing new apps to help clinicians to make earlier sense of complex patient behaviors through innovative tech, big data and AI. Join us to learn from their journey and experiences in adapting novel technology solutions into the NHS by speaker James Chapman, Co-founder and Product lead for Decently Ltd who will talk about the 'The Challenges and Pitfalls of Developing a New Digital Health Technology in Collaboration with the NHS' on 26th June between 2-3pm, via zoom. The Webinar will also be chaired by a health economist Dr Alexander Thompson, Senior Lecturer at the Manchester Centre for Health Economics (MCHE). Everybody is welcome to attend and to ask questions during the Q&A session. Click here to register: https://lnkd.in/epNSt-E7

We are excited to announce the upcoming the CAMS scientific symposium on ‘Alternative approaches for human-relevant toxicity assessments' on 10th July 2024 from 12:30pm. The Keynote lecture will be given by Professor Menna Clatworthy (University of Cambridge), and guest speakers from the Investigative Toxicology Leaders Forum will also be in attendance. In this event we will showcase alternative approaches and recent advances in complex in vitro models (e.g MPS) from industry and academia to complement traditional in vivo studies, and how these are used to investigate human-relevant toxicity and translate these findings to the clinic. With speakers from AZ, GSK, Bayer, Sanofi, Merck, Novartis and Abbvie, as well as expertise from the MRC’s Toxicology Unit and the Centre for Drug Safety Science, we will give a snapshot of where the field of medicines safety is going, and where we can learn from successes of the past to accelerate moving forward with novel therapeutic modalities. Please register for the event here: https://lnkd.in/e4p4yZWV

Another month, another exciting G2T webinar! “Gateway to Translation” (G2T) #webinar series is a joint initiative between CATS (University of Cambridge) and Translation Manchester (The University of Manchester). These monthly Zoom - based online talks are aimed to inform academics about new #technologies and #translationalresearch developed in #pharma/ #medtech/ #biotech sector, as well as to facilitate collaboration between #academia and commercial sphere. Next webinar (22nd May, 2 pm) will be delivered by Dr Atefeh Mobasseri, Field Application Scientist at CN Bio Ltd. CN Bio is a Cambridgeshire based company, which specialises in the development and applications of organ-on-a-chip technology. The name of the talk: “Taking Organoids to the Next Level: State of Art Organ-on-a-chip Technology” Webinar will be chaired by Prof Matthias Zilbauer MD PhD, Clinical Professor of Paediatric Gastroenterology at University of Cambridge and a Group leader in Cambridge Stem Cell Institute. Everybody is welcome to attend and to ask questions during the Q&A session. Registration link: https://lnkd.in/eeKTSYkR

Next week, we are continuing with our “Gateway to Translation” G2T webinar series - a joint initiative between CATS (University of Cambridge) and Translation Manchester (The University of Manchester). These monthly Zoom - based online talks are aimed to inform academics about new technologies and translational research developed in pharma/medtech/biotech sector, as well as to facilitate collaboration between academia and commercial sphere. Next webinar (30th April, 2 pm) will be delivered by Dr Mat Robinson, senior vice-president for research at Microbiotica ltd. Microbiotica is a Cambridgeshire based company, which identifies gut bacteria linked to phenotype of diseases in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. The name of the talk: “Discovery of microbiome-based therapeutics: A clinic-first approach in IBD and immune-oncology enabled by precision microbiome profiling.” Webinar will be chaired by Dr Virginia Pedicord, a Group leader in the Department of Medicine, University of Cambridge. Everybody is welcome to attend and to ask questions during the Q&A session. Registration link: https://lnkd.in/dmVGmbMX